Abstract
Objective: Comparison of fertility between frozen-thawed and fresh sperm using ICSI was done to detect the presence of occult cyro-damage. A non human primate model was used due to ethical constraints in the human for this evaluation using normal male sperm and oocytes. Design: A prospective study in a primate model at a regional primate research center. Methods: Semen collected from male rhesus monkeys by penile electroejaculation was extended with either A) 80 mM sucrose, 5% glycerol in TALP-Hepes or B) 60 mM glucose, 12% egg yolk, 8% skim milk, 3% glycerol in TEST buffer. Both groups were equilibrated 90 min at 4°C before freezing in liquid nitrogen (LN) vapors for 30 min and storage in LN for >24 hrs. Straws were thawed 5 sec in 37°C water bath, washed twice and diluted to 5 × 106/ml. ICSI was performed on mature oocytes retrieved from cycling females exposed to follicular stimulation with recombinant human hormones. Injected oocytes were co-cultured on BRL cells and observed for the presence of 2 pronuclei or cleavage as evidence of fertilization. Results: Prefreeze motilities of samples frozen with extenders A (n=8) and B (n=9) were similar (>80%). Post-thaw percent motility was higher with extender B (31.2 ± 8.3% vs 58.6 ± 7.3%, P<0.05) and with greater forward progression, however, both methods provided adequate samples for ICSI. In 4 ICSI experiments with F/T sperm from method A, oocytes fertilized at a lower rate (16 of 39; 41%) compared to 30 of 38 oocytes injected with fresh sperm (79%) (P<0.01). Similarly, in 5 experiments with F/T sperm from method B, 22 of 40 oocytes (55%) fertilized compared to 34 of 40 oocytes injected with fresh sperm (85%) (P<0.01). Development to blastocyts by day 8 was similar in all groups (50–70%). Conclusions: Reduced fertilization rates after ICSI with F/T sperm suggest a deficiency in oocyte activating ability even though good motility is recovered post-thaw. While no loss in embryonic development was observed, ICSI with F/T sperm may require superimposition of oocyte activation strategies for efficient use in banking of valuable genetic stocks. Supported by NIH RR12804, A142709, and Ares Advanced Technology, Inc.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.